SEC Form 4 · accession 0001553878-18-000029

ALNYLAM PHARMACEUTICALS, INC. · ALNY

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — SVP, GC & Secretary

Period of report

Mar 20, 2018

Accepted (ET)

Mar 22, 2018 · 6:18 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001178670

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Mar 20, 2018	M	1,562	$42.22	A	16,062	D
Common Stock	Mar 20, 2018	S	100	$146.36	D	15,962	D
Common Stock^F2	Mar 20, 2018	S	462	$147.79	D	15,500	D
Common Stock^F3	Mar 20, 2018	S	500	$149.97	D	15,000	D
Common Stock^F4	Mar 20, 2018	S	200	$151.48	D	14,800	D
Common Stock^F5	Mar 20, 2018	S	300	$152.79	D	14,500	D
Common Stock^F6	holding	—	—		—	257	I	by Managed Account

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F7	$42.22	Mar 20, 2018	M	1,562	D	—	Dec 20, 2026	Common Stock	1,562	17,189	D

F1All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2017.
F2Sale prices ranged from $147.40 to $148.05
F3Sale prices ranged from $149.60 to $150.54
F4Sale prices ranged from $151.46 to $151.50
F5Sale prices ranged from $152.48 to $153.30
F6The reporting person owns 257 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
F7The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.